Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 1:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Florbetaben F18 Clear all
Completed No phase listed Observational Accepts healthy volunteers

Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease

NCT04510168
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
11C-ER176, [F-18]MK-6240, Florbetaben, Magnetic Resonance Imaging
Drug · Other
Lead sponsor
Jose Gutierrez, MD, MPH
Other
Eligibility
50 Years and older
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 22, 2026, 1:44 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

NCT04576793
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176, 18F-MK6240, 18F-Florbetaben, Lumbar Puncture
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Completed Phase 3 Interventional

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

NCT05184088
View directory record Official record
Conditions
Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis
Interventions
[18F]florbetaben
Drug
Lead sponsor
Lantheus Germany GmbH
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Kansas City, Kansas • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

NCT04840979
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176, 18F-florbetaben
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Vascular Disease in Aging and Dementia

NCT03075007
View directory record Official record
Conditions
Alzheimer Disease, White Matter Hyperintensities, Dementia, Aging
Interventions
Florbetaben F18, Transcranial Doppler
Radiation · Procedure
Lead sponsor
Columbia University
Other
Eligibility
60 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 22, 2026, 1:44 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 4

NCT05617014
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Inflammation in Alzheimer's Disease With 11C-ER176

NCT03744312
View directory record Official record
Conditions
Alzheimer Disease
Interventions
11C-ER176, Florbetaben
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 22, 2026, 1:44 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
View directory record Official record
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Completed No phase listed Observational

Florbetaben PET Imaging in PPA

NCT04720001
View directory record Official record
Conditions
Primary Progressive Aphasia, Alzheimer Disease
Interventions
Florbetaben F18, PET
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 22, 2026, 1:44 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

NCT05337774
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
[18F]PI-2620
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
25 Years to 54 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 22, 2026, 1:44 AM EDT
Completed Early Phase 1 Interventional

Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People

NCT02669225
View directory record Official record
Conditions
Normal Physiology
Interventions
[18F]florbetaben
Other
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Completed Not applicable Interventional

Neuraceq™ PET for Detection of Brain Changes in Young Athletes Post-concussion

NCT05270083
View directory record Official record
Conditions
Concussion, Brain
Interventions
NeuraCeq PET imaging with intravenous (IV) dose of 300MBq of Neuraceq™ ([F-18]Florbetaben)
Diagnostic Test
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 22, 2026, 1:44 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

NCT04396873
View directory record Official record
Conditions
Parkinson's Disease, Dementia, Alzheimer's Disease, ALS, Mild Cognitive Impairment
Interventions
11C-MC1, 11C-PS13, 18f-florbetaben
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 99 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Withdrawn No phase listed Observational

Biomarkers in Neurodegenerative Diseases

NCT04055532
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD), Parkinsons Disease With Dementia (PDD), Transient Epileptic Amnesia (TEA), Temporal Lobe Epilepsy (TLE), Spinocerebellar Ataxias (SCA), HIV Associated Neurocognitive Disorder (HAND), Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS)
Interventions
Neuraceq
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Timeline
2019 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Sep 22, 2026, 1:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Imaging of Cognition, Learning, and Memory in Aging

NCT01297114
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Florbetaben
Drug
Lead sponsor
Yaakov Stern
Other
Eligibility
20 Years to 70 Years
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Sep 22, 2026, 1:44 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

NCT02531360
View directory record Official record
Conditions
Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
Interventions
[18F]MNI-815 (MNI-815)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 22, 2026, 1:44 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

NCT07169630
View directory record Official record
Conditions
Alzheimer s Disease, Mild Cognitive Impairment, Healthy
Interventions
18F-PF974, 18F-florbetaben
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
50 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
Drug
Lead sponsor
Tharick Pascoal
Other
Eligibility
18 Years to 90 Years
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

NCT03706261
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-MK-6240, 18F-Florbetaben
Drug
Lead sponsor
Adam Brickman
Other
Eligibility
35 Years to 85 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Sep 22, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Inflammation in Alzheimer's Disease

NCT02831283
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
11C-PBR28, 18F-Florbetaben, Lumbar puncture (optional)
Drug · Procedure
Lead sponsor
Patrick Lao
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 22, 2026, 1:44 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

NCT07787169
View directory record Official record
Conditions
Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Irvine, California • Daytona Beach, Florida • Lady Lake, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Alzheimer's Disease Research Center (ADRC) PET Component Study

NCT07758660
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment (MCI), Dementia
Interventions
18F-MK6240, 18F-Florbetaben (FBB)
Drug
Lead sponsor
Patrick Lao
Other
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2033
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT07787182
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Interventions
LY4405094, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
10
States / cities
Irvine, California • Daytona Beach, Florida • Lady Lake, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 22, 2026, 1:44 AM EDT
Completed Early Phase 1 Interventional

PET/MRI Evaluation of Cardiac Amyloid

NCT03119558
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
18F-Florbetaben (Neuraceq®) PET/MRI
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 22, 2026, 1:44 AM EDT